Breaking News, Trials & Filings

Trials & Filings in Brief: Oct. 9, 2013

Alkermes, Allegro, Bayer, BDSI, Medivir, Pfizer, Portola, and The Medicines Company

Phase I
Medivir posts new seven-day data of MIV-711 in osteoarthritis . . . read more

Portola begins proof-of-concept for SyK/JAK inhibitor . . . read more

Phase II
Alkermes aligns with FDA on development plans . . . read more

Allegro cleared for ophthalmic trials . . . read more

Phase III
Pfizer releases topline data for JAK inhibitor . . . read more

TMC enrolls first Angiomax PEI patient . . . read more

Filings
Bayer PAH/CTEPH drug approved . . . read more

BDSI Files Bunavail NDA . . . read more

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters